Christopher Rovaldi Sells 14,000 Shares of Acceleron Pharma Inc. (XLRN) Stock
Acceleron Pharma Inc. (NASDAQ:XLRN) SVP Christopher Rovaldi sold 14,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total value of $537,740.00. Following the completion of the transaction, the senior vice president now owns 28,232 shares of the company’s stock, valued at $1,084,391.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of Acceleron Pharma Inc. (XLRN) traded up 0.50% during mid-day trading on Thursday, hitting $39.94. 465,608 shares of the stock traded hands. The stock has a 50-day moving average of $35.47 and a 200-day moving average of $30.78. Acceleron Pharma Inc. has a 52 week low of $23.07 and a 52 week high of $41.69. The company’s market cap is $1.55 billion.
Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.12). Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The company had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $3.69 million. During the same quarter in the previous year, the company earned ($0.59) EPS. The firm’s quarterly revenue was down 3.1% compared to the same quarter last year. Analysts anticipate that Acceleron Pharma Inc. will post ($2.70) EPS for the current year.
WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/14/christopher-rovaldi-sells-14000-shares-of-acceleron-pharma-inc-xlrn-stock.html.
XLRN has been the subject of several analyst reports. Cann reiterated a “buy” rating and issued a $40.00 price target on shares of Acceleron Pharma in a report on Thursday, June 1st. Piper Jaffray Companies boosted their price target on Acceleron Pharma from $32.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, June 26th. BidaskClub upgraded Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, June 21st. Goldman Sachs Group, Inc. (The) initiated coverage on Acceleron Pharma in a report on Wednesday, May 17th. They issued a “sell” rating and a $20.00 price target for the company. Finally, FBR & Co reiterated a “buy” rating on shares of Acceleron Pharma in a report on Thursday, May 18th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Acceleron Pharma has an average rating of “Buy” and a consensus price target of $42.21.
A number of hedge funds have recently added to or reduced their stakes in XLRN. Parametric Portfolio Associates LLC raised its holdings in shares of Acceleron Pharma by 3.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 9,456 shares of the biopharmaceutical company’s stock valued at $287,000 after purchasing an additional 355 shares in the last quarter. TD Asset Management Inc. raised its holdings in shares of Acceleron Pharma by 0.8% during the 2nd quarter. TD Asset Management Inc. now owns 78,800 shares of the biopharmaceutical company’s stock valued at $2,395,000 after purchasing an additional 600 shares in the last quarter. Tudor Investment Corp ET AL raised its holdings in shares of Acceleron Pharma by 8.5% during the 1st quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock valued at $241,000 after purchasing an additional 716 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Acceleron Pharma by 9.7% during the 2nd quarter. Legal & General Group Plc now owns 10,470 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 923 shares in the last quarter. Finally, Teachers Advisors LLC raised its holdings in shares of Acceleron Pharma by 2.1% during the 1st quarter. Teachers Advisors LLC now owns 46,080 shares of the biopharmaceutical company’s stock valued at $1,220,000 after purchasing an additional 942 shares in the last quarter. Institutional investors own 88.07% of the company’s stock.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.